Skip to main content
. 2024 Dec 27;17:3033–3044. doi: 10.2147/CCID.S498987

Figure 9.

Figure 9

The RXI-231 formulation was tested in the MatTek EpiDerm skin irritation model. Briefly, the 3 dimensional skin construct is treated with the test article and viability is assessed after 24 hours. Irritancy is predicted if the viability is reduced to lower than 50% of the viability of the negative controls. RXI-231 in formulation showed no reduction in viability.